Prevalence and profile of pregabalin abuse in patients visiting a drug de-addiction center

Pregabalin, a Gamma aminobutyric acid (GABA) analog, is widely prescribed for neuropathic pain, anxiety disorders, and epilepsy. However, its potential for misuse has raised significant public health concerns globally. The misuse of pregabalin is increasingly reported in our part of the world, where substance abuse is already a growing issue due to social, political, and psychological vulnerabilities.

This study aimed to assess the profile and prevalence of pregabalin abuse among patients visiting a de-addiction center in Kashmir.

A cross-sectional study was conducted among 43 patients admitted to a de-addiction center in Kashmir over 3 months. Data on sociodemographics, substance use patterns, and reasons for misuse were collected using a semi-structured questionnaire.

Out of the 43 patients, 19 (44.2%) reported pregabalin as the primary substance abused, while 24 (55.8%) reported it as a secondary substance. Males constituted 93% of the sample, with the majority (72.1%) aged 18-35 years. Polysubstance use was observed in 65% of patients, primarily involving opioids (51.2%) and synthetic drugs such as tramadol and codeine (39.5%). Common reasons for abuse included anxiety relief (55.8%), pain relief (37.2%), and recreational use (30.2%).

Pregabalin abuse is an emerging issue in Kashmir, often associated with polysubstance use and psychiatric comorbidities. Urgent steps are needed to regulate its availability, raise awareness regarding its abuse potential, and improve access to mental health services in the region.